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ess: richeldi.luca@unimSummary Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease
leading to death within a few years of diagnosis despite medical therapy. On the
basis of methodologies of the Cochrane collaboration, this overview discusses the
evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most
common medical therapy in use for IPF, are lacking. A few small studies have been
carried out on the efficacy of many non-steroid immunosuppressive agents, and the
results have been generally disappointing. The most extensively studied medical
therapy, gamma interferon, showed a significant effect in a small randomized study,
but its efficacy was not confirmed in a larger randomized-controlled trial. The long-
awaited good news for patients affected by this deadly disease, and for their
physicians, could come in the near future from large randomized-controlled trials
with gamma interferon or other immunomodulatory agents.
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The aim of this overview is to describe the level of
evidence available on the efficacy of corticoster-
oids and immunosuppressive, antifibrotic or immu-
nomodulatory therapies in the treatment of
idiopathic pulmonary fibrosis (IPF). Such a systema-
tic approach is needed, as many studies on the
treatment of IPF are weakened by the fact that the
diagnostic criteria used to define the study popula-
tions are not those currently agreed upon in
consensus guidelines. Therefore, to consolidate
F. Luppi et al.1036the evidence derived from single studies at levels
that would provide a guide to the clinical manage-
ment of IPF patients, studies need also to be
evaluated for both patients’ characteristics and
study design. Cochrane reviews summarize the
highest quality evidence for efficacy of interven-
tions, by incorporating results from randomized-
controlled trials.1 The Airways Group of the
Cochrane Collaboration has recently published
two systematic reviews on the treatment of IPF,2,3
in which only studies of adult patients with a
diagnosis of IPF based upon adequate clinical and
radiological criteria in accordance with current
guidelines4 were included. The present review is
largely based on the results of these two Cochrane
reviews.The pathogenesis of idiopathic
pulmonary fibrosis
IPF is a clinical and pathological entity, for which
precise diagnostic criteria have been recently
defined4 and significant advances in the under-
standing of underlying mechanisms have been
made. As the basis for a therapeutic approach to
any disease mainly resides in understanding the
mechanisms leading to the disease, a brief sum-
mary of our current knowledge about IPF pathogen-
esis follows.
Many studies have questioned the role of chronic
lung inflammation in IPF pathogenesis.5–7 According
to the ‘‘inflammatory’’ hypothesis, IPF is a disease
in which pulmonary fibrosis is directly caused by
chronic inflammation; therefore, if in theory the
inflammation cascade could be interrupted before
irreversible tissue injury occurs, fibrosis might be
avoided. However, chronic inflammation is not
required for the development of a fibrotic re-
sponse, and IPF is instead the result of a process
similar to abnormal wound healing, in which
altered signalling mechanisms originate from acti-
vated epithelial and mesenchymal cells.8 The
distinctive feature of IPF is not lung inflammation
but, rather, the predominance of fibroblastic foci.
They are the hallmark histopathologic feature of
IPF, and their number directly correlates with
prognosis, whereas the level of interstitial inflam-
mation is less predictive.9 After injury, the alveolar
epithelium initiates a wound healing process to
restore its barrier integrity. In IPF, this process
seems slow and inadequate, leading to a marked
disruption in the integrity of the alveolar epithe-
lium. This process differs from the normal wound
healing model mainly in the lack of adequate re-epithelialization.5 In IPF, epithelial cells express
several cytokines and growth factors, such as
platelet-derived growth factor, transforming
growth factor b (TGF-b), and tumour necrosis
factor alpha, all of which are central mediators in
the development of pulmonary fibrosis.10 Recent
findings suggest that alveolar epithelial cells are
the primary source of cytokines and growth factors
involved in fibroblasts migration and proliferation,
and myofibroblasts differentiation, which are found
to be the primary source of heightened type I
procollagen gene expression in animal model of
lung injury and fibrosis.11 One of the current
hypotheses for the causation of IPF suggests that
a still unidentified stimulus produces repeated
episodes of acute lung injury; wound healing at
the sites of injury ultimately leads to fibrosis, with
loss of lung function. If this hypothesis is proved to
be true, then an effective therapeutic strategy
should point to modulation of epithelial cell
activation, fibroblast replication and matrix deposi-
tion more than to suppression of the inflammatory
process.The diagnosis of idiopathic pulmonary
fibrosis
IPF is the most clinically relevant entity of the
heterogeneous group of pulmonary disorders of
unknown aetiology known as idiopathic interstitial
pneumonias. Idiopathic interstitial pneumonias
comprise a number of clinical and pathological
entities that are sufficiently different from one
another to be considered separate disease entities.
These lung diseases have been described by lung
pathologists by means of various classifications, in
which the main entity is always reported as ‘‘usual
interstitial pneumonia’’ (UIP).12–14 However, var-
ious terms have been used to identify the clinical
entity associated with the different histological
patterns (e.g. diffuse interstitial fibrosis, diffuse
fibrosing alveolitis, cryptogenic fibrosis alveolitis,
classical interstitial pneumonitis-fibrosis, diffuse
interstitial pneumonitis and IPF).15 Therefore, for
some time, patients with histologically different
forms of interstitial pneumonias have been grouped
together. With the demonstration of different
survival and responses to steroids associated with
different histological patterns, the term IPF is
restricted to those patients with a histological
appearance of UIP on a surgical lung biopsy.4 The
most relevant differential diagnosis is between IPF,
and UIP and the entity known as non-specific
interstitial pneumonia (NSIP).16 NSIP occurs a
Corticosteroid and immunomodulatory agents in IPF 1037decade or more earlier than IPF17 and, unlike IPF,
may occur in children.16 There is neither sexual
predominance nor association with cigarette smok-
ing. The NSIP histological pattern encompasses a
broad spectrum of histological features with vary-
ing degrees of alveolar wall inflammation or
fibrosis.16 At the fibrosing end of the spectrum of
NSIP, the pattern is of dense or loose interstitial
fibrosis in varying degrees, and the connective
tissue is temporally homogeneous.16 Fibroblast
foci, the key lesion that gives the UIP pattern the
appearance of temporal heterogeneity, are absent
or inconspicuous. The computed tomography (CT)
features show that ground glass attenuation is the
predominant finding in most cases. It is most
commonly bilateral and symmetrical, with sub-
pleural predominance. However, in a study of 50
patients, CT pattern was found to be indistinguish-
able from UIP in 32% of patients.18 The prognosis of
NSIP is more variable than in IPF, and seems to
depend on the extent of fibrosis.19,20 Some patients
experience almost complete recovery. Unlike IPF,
most of the remainder stabilize, improve sponta-
neously or remain on corticosteroid treatment (Fig.
1).21 Relapse may occur; only a few patients
progress and die compared with IPF.
In IPF, the onset of symptoms is usually gradual,
with dyspnoea the most prominent and disabling
symptom. These patients are usually aged between
50 and 70 years. Cigarette smoking has been
identified as a potential risk factor for the disease.
IPF is characterized by spatial and temporal
heterogeneity, with areas of mature fibrosis juxta-
posed to active fibroblastic foci and normal lung.
Chest radiography in IPF is almost always abnormal,
and reveals diminished lung volumes and sym-100
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Figure 1 Patients with usual interstitial pneumonia
(UIP)/idiopathic pulmonary fibrosis (IPF) had a signifi-
cantly worse survival compared with patients with non-
specific interstitial pneumonia (NSIP) and patients with a
heterogeneous group of interstitial lung diseases. (Re-
produced with permission from Bjoraker et al.21).metric, bibasilar and peripheral reticulations. With
high-resolution CT (HRCT), typical features of IPF
are honeycomb cysts, distorted intralobular reticu-
lations and traction bronchiolectasis, with a strik-
ing predilection for the lung periphery and bases.
Ground-glass attenuation is typically admixed with
fibrosis, and is rarely the dominant pattern.22
Transbronchial lung biopsy is not an adequate
tool to identify the pathological pattern of UIP, but,
together with bronchoalveolar lavage, can be
helpful to exclude alternative diagnoses, in parti-
cular, sarcoidosis.23 Definitive histological diagnosis
of IPF requires a surgical lung biopsy. In the
presence of a surgical biopsy showing a UIP pattern,
the diagnosis of IPF requires (1) exclusion of other
known causes of interstitial lung disease; (2)
characteristic abnormalities on conventional chest
X-ray or HRCT; and (3) abnormal pulmonary func-
tion tests, showing restriction, impaired gas ex-
change (or both), decreased PaO2 with rest or
exercise or decreased DLCO.
22–24
In conclusion, the definite diagnosis of IPF
requires a compatible clinical history, the exclusion
of other known causes of other interstitial lung
diseases (such as drug injuries, environmental
exposures or collagen vascular disease) and a
surgical biopsy showing the pattern of UIP. How-
ever, surgical biopsy cannot be carried out in all
patients with a clinical and radiological suspect of
IPF. Exclusion of other known causes of interstitial
lung diseases and abnormal pulmonary function
tests, which include evidence of restriction and
characteristic radiological abnormalities, particu-
larly HRCT, increases the likelihood of a correct
clinical diagnosis of IPF. Together with the recogni-
tion that IPF is characterized by a distinct
pathology, many studies have focused on the
extremely poor prognosis of patients with IPF, as
defined above; sadly, these patients usually die
within 5 years of diagnosis,25 as do most patients
with lung cancer. As in lung cancer, a clinical
response to the current therapeutic agents is
unusual, and treatment is unlikely to alter outcome
in most patients. Current guidelines, based upon
consensus, indicate prednisone, azathioprine and
cyclophosphamide as the basis for IPF treatment;4
however, it is common for chest physicians to
observe that these drugs are ineffective in most
patients with IPF. Therefore, on the basis of
methodologies of the Cochrane collaboration, this
review discusses the evidence for IPF therapy,
drawing on the findings of two systematic reviews
on the treatment of IPF.2,3 Drugs have been divided
into two main groups: those included in current
guidelines and those not (yet) included in such
documents.
F. Luppi et al.1038Drugs recommended by current
guidelines
Corticosteroids
On the basis of early observations demonstrating
inflammatory cells in the distal air space, numerous
studies have investigated the use of corticosteroids
in IPF. Some early studies suggested that corticos-
teroids reduced the so-called ‘‘ground-glass opa-
cities’’ of HRCT in people with interstitial
pneumonia, and that this reduction paralleled
improvement in pulmonary function.26 Interest-
ingly, although HRCT ground-glass attenuation is
reduced after steroid treatment, the progression to
irreversible honeycomb fibrosis is not altered.27
Clearly, in these studies, lung diseases other than
IPF were included. A recent Cochrane review2
explored the efficacy of corticosteroids in the
treatment of adults with IPF. Of 15 studies
potentially eligible for meta-analysis, no eligible
studies were found after review because of
inadequate methodologies; therefore, no data
were available for inclusion in a meta-analysis. At
present, no evidence for an effect of corticoster-
oids in IPF is available. Considering the enormous
empirical clinical experience and recent develop-
ments in the understanding of the pathogenesis of
IPF, it is reasonable to assume that appropriate
trials to investigate the efficacy of steroids in IPF
will never be carried out. Alternatively, a trial
of steroids should be considered for those
patients with idiopathic interstitial pneumonia
but without a definite diagnosis of IPF, when
another diagnosis cannot be ruled out. In such
cases, a trial of prednisone should be limited
to 3–6 months, and objective improvement in
physiological measures, radiographical findings
and clinical symptoms should be rigorously
assessed. Longer trials of prednisone and the
prolonged use of cytotoxic agents remain contro-
versial. In the absence of measurable improve-
ment, steroid therapy should, in most instances, be
discontinued.Azathioprine
Azathioprine is an antimetabolite. Usually taken
orally, it is well absorbed by the gastrointestinal
tract. It is primarily metabolized in the liver, where
its side chain is removed. Through these actions,
azathioprine blocks most T-cell functions, inhibits
primary antibody synthesis and decreases the
number of circulating monocytes and granulo-
cytes.28Only three randomized-controlled trials have
studied the effect of this cytotoxic agent in the
management of IPF. The first reported trial Fulmer
et al.29 was published only as an abstract. This
study was a 12-month, randomized, double-blind,
placebo-controlled trial, in which 26 patients with
IPF were randomly assigned to receive either
prednisone and placebo or prednisone and
azathioprine (2.5mg/kg/day). Five patients devel-
oped drug toxicity: two in the placebo group and
three in the azathioprine group. No significant
differences in outcome were reported.
The trial by Winterbauer30 was a prospective,
randomized, double-blind, placebo-controlled
trial, which included 27 patients with IPF, 13 of
whom received prednisone and placebo, and 14 of
whom received prednisone and azathioprine. Pa-
tients were given prednisone at an initial dose of
1.5mg/kg/day for 2 weeks, with a bi-weekly taper
until a maintenance dose of 20mg/day was
reached. Azathioprine was given at 3mg/kg/day
to a maximum of 200mg/day. The number of
patients who showed a decrease in alveolar–arter-
ial difference in resting partial pressure of oxygen
was greater in the azathioprine group (seven out of
14) than in the placebo group (two out of 13), a
difference that just achieved statistical signifi-
cance. A trend toward clinical improvement in
the azathioprine group was noticed, but no
significant difference was observed in changes in
forced vital capacity (FVC) or diffusing capacity for
carbon monoxide. Mean survival time for the
azathioprine group was 43 months, with eight
survivors (57%). Mean survival time in the placebo
group was 34 months, with four survivors (31%). The
total number of adverse effects was similar in the
two groups.
The trial by Raghu et al.31 reported results of 27
newly diagnosed patients with IPF, previously
untreated, who were enrolled in a prospective,
double-blind, randomized, placebo-controlled
study to compare the therapeutic effect of com-
bined prednisone/azathioprine with that of pre-
dnisone/placebo. All patients underwent open lung
biopsy. Prednisone was started at 1.5mg/kg/day
(not to exceed 100mg/day) for the first 2 weeks,
followed by a bi-weekly taper to a maintenance
dose of 20mg/day. Azathioprine was given as a
daily dose of 3mg/kg (not to exceed 200mg/day).
Changes in lung function after 1 year, as measured
by alveolar–arterial difference in resting partial
pressure of oxygen, FVC, and single-breath diffus-
ing capacity for carbon monoxide, were all some-
what better in the azathioprine/prednisone group
than in the prednisone/placebo group, although
none of these comparisons was statistically
Corticosteroid and immunomodulatory agents in IPF 1039significant. Six of 14 (43%) patients randomized to
azathioprine/prednisone died during the 9-year
follow-up period, compared with 10 out of 13
(77%) patients randomized to prednisone/placebo.
A Cox model survival analysis showed a non-
significant, but potentially large, survival advan-
tage for azathioprine/prednisone. When adjusted
for age as a continuous variable, there was a
significant difference favouring the combination of
azathioprine/prednisone (P ¼ 0:02). There were a
large number of adverse events, mostly related to
prednisone, but with no significant differences
between groups. Using evidence-based criteria,
this study is the only one that could be considered
to be of high quality (Table 1). This is probably the
reason that current guidelines recommend the use
of azathioprine in IPF patients not responding to
steroids.
In conclusion, the addition of azathioprine to oral
corticosteroid therapy seems to provide little or no
benefit in the treatment of patients with IPF,
although the drug seemed to be well tolerated in
these studies.Cyclophosphamide
Cyclophosphamide is an alkylating agent primarily
used for the treatment of autoimmune disease and
cancer. In a randomized-controlled study, Johnson
et al.32 compared the effects of prednisolone plus
cyclophosphamide with those of alternate-day,
low-dose prednisolone in 43 patients with pre-
viously untreated fibrosing alveolitis, diagnosed
mainly on clinical grounds. Patients received either
alternate-day, high-dose prednisolone or the mini-
mum dose to maintain early improvement. Patients
in the cyclophosphamide/prednisolone series re-
ceived 100, 110, or 120mg of cyclophosphamide
daily (depending on body weight) plus 20mg of
prednisolone on alternate days. Treatment was
continued indefinitely, or changed to the alter-
native regimen if the patient deteriorated, failed
to improve, or developed drug toxicity. For
response to treatment (as judged by change in
breathlessness score, radiographic appearance and
lung function), patients were classified as im-
proved, stable or deteriorating. Improvement
occurred at one or more assessments in seven out
of the 22 patients in the prednisolone series and in
five of the 21 patients in the cyclophosphamide/
prednisolone series. After 3 years, only two of the
22 patients in the prednisolone series were still
improved, and three were stable; in comparison,
one out of the 21 patients in the cyclophospha-
mide/prednisolone series was still improved, andseven were stable. Life table analysis suggested
that there was better survival of patients in the
cyclophosphamide/prednisolone series, but it was
not significant. After 3 years, 10 out of 22 patients
in the prednisolone series had died, compared with
three out of 21 patients in the cyclophosphamide/
prednisolone series. With death or failure of first-
treatment regimen as outcome, there was a
significant advantage to the patients receiving
cyclophosphamide/prednisolone. This advantage
was explained in part by the better lung volumes
in this group on admission. Analyses of subgroups
according to total lung capacity (TLC) on admission
showed that patients with a TLC below 60%
predicted did badly and those with a TLC of 80%
or more predicted did well with both regimens.
Therefore, the combination of low-dose predniso-
lone and cyclophosphamide was as effective as
high-dose prednisolone and was well tolerated.
However, patients in the cyclophosphamide/pred-
nisolone group received a significant dose of
prednisolone that may have been responsible for
the apparent benefit; alternatively, cyclophospha-
mide may have had a corticosteroid-sparing effect,
boosting the effective dose. Methodologically, the
trial was inadequate, with no blinding and poor
procedures that may have broken down, as there
was a trend toward lower baseline TLC and FVC in
the prednisolone group. Finally, there was signifi-
cant disease heterogeneity in the study population;
five patients in each group had connective tissue
disorders, and it is highly likely that patients with
histological patterns other than UIP were included.Drugs not included among those
recommended by current guidelines, but
with a rationale for use in idiopathic
pulmonary fibrosis
Gamma interferon-1beta
Gamma interferon (IFN-g) is the main Th1 cytokine,
and recent advances have pointed to a lack of Th1
response as a key element in IPF. Therefore, its use
in IPF treatment has been the subject of well-
designed and large studies. IFN-g is an endogen-
ously produced cytokine with various effects,
including antifibrotic, anti-infective, antiprolifera-
tive and immunomodulatory. Its dose-dependent
inhibition of fibroblast proliferation, collagen-ma-
trix deposition and collagen synthesis has been
demonstrated in vitro and in rodent models.
Studies of lung tissue and blood from patients
with IPF have found absolute and relative deficits in
Table 1 Published studies on medical therapy for IPF.
Reference Year Study design Study
population
(n)
Diagnostic criteria Study treatments Level of
evidence*
Winterbauer30 1991 Randomized, double-blind, placebo-
controlled, prospective study
27 Not specified Prednisone + placebo (n ¼ 13) vs.
prednisone + azathioprine (n ¼ 14)
B
Raghu et al.31 1991 Randomized, double-blind, placebo-
controlled, prospective study
27 Open lung biopsy Prednisone + placebo (n ¼ 13) vs.
prednisone + azathioprine (n ¼ 14)
A
Johnson et al.32 1989 Randomized-controlled study 43 Open lung biopsy in
33 out of 43 patients
Prednisone high dose (n ¼ 22) vs.
cyclophosphamide + prednisone
low dose (n ¼ 21)
D
Douglas et al.44 1998 Randomized, prospective study 26 HRCT findings and/or
open lung biopsy
D
Ziesche et al.38 1999 Randomized, prospective study 18 Open lung biopsy Prednisolone (n ¼ 9) vs.
prednisolone + IFN-g-1b (n ¼ 9)
A
Raghu et al.39 2004 Randomized, double-blind, placebo-
controlled, prospective study
330 Open lung biopsy,
HRCT findings, or
both
A
HRCT, high-resolution computed tomography.
*Assessed on the basis of criteria used in the Cochrane reviews.2,3
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Figure 2 Survival curves (Kaplan–Meier estimates) for
patients affected by idiopathic pulmonary fibrosis and
treatred with IFN-gamma or placebo in a large rando-
mized, placebo-controlled trial. (Reproduced with per-
mission from Raghu et al.39).
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more, in a bleomycin-induced model of lung
fibrosis, exogenous IFN-g downregulated the tran-
scription of the gene for TGF-b1.35
The three major classes of interferons are alpha,
beta, and gamma. As IFN-a and IFN-b share
components of the same receptor, they have been
referred to as type I interferons. IFN-g uses a
separate receptor system, and has been referred to
as type II interferon. IFN-a and IFN-b are secreted
by virus-infected cells, whereas IFN-g is secreted
mainly by T cells, natural killer cells and macro-
phages.36 Compared with IFN-a and IFN-b, the gene
for IFN-g is located on a different chromosome, it
binds to a different receptor, its structure is
different and it is the only interferon that is
considered to be capable of activating macro-
phages and inducing HLA class II antigens.37 Inter-
ferons do not normally circulate, are formed
constitutively by most cells and function physiolo-
gically by autocrine or paracrine mechanisms.36
IFN-g converts macrophages from a resting to an
active state, and induces the synthesis of an array of
receptors for binding to pathogens and endothelia,
degradative enzymes, transcription factors and
cytokines involved in host defense. These broad
immunoregulatory activities allow IFN-g to play an
important role in controlling diseases caused by
intracellular bacteria (e.g. Listeria and Mycobacter-
ium), parasites (e.g. Leishmania and Toxoplasma)
and fungi (e.g. Cryptococcus). The broad activity of
IFN-g is still only partially understood. However,
several key immunoregulatory roles of IFN-g are
known: (1) improved antigen presentation; (2)
enhanced killing of intracellular pathogens, which
induces the synthesis of enzymes in phagocytes that
are involved in the generation of reactive oxidants
(e.g. superoxide, hydrogen peroxide, and nitric
oxide); these reactive species are involved in the
killing of intracellular and some extracellular infec-
tions; (3) heightened capacity for microbial killing;
and (4) enhanced recruitment of leukocyte-en-
hanced macrophage activity and increased intracel-
lular concentration of antimicrobials.
Ziesche et al.38 reported the findings of a small,
non-placebo-controlled, randomized trial of long-
term treatment with IFN-g-1b and low-dose pre-
dnisolone in patients with IPF. They found striking
improvement in lung function in the nine patients
treated with IFN-g-1b in addition to prednisolone,
compared with those who received only predniso-
lone, over the course of 1 year. All nine patients
treated with IFN-g-1b showed statistically signifi-
cant improvement in TLC and resting partial
pressure of arterial oxygen, and eight of them
showed improvement in partial pressure of arterialoxygen on maximal exertion. In contrast, eight of
the nine patients in the control group, who
received prednisolone alone, had a decline in all
three measurements over the same period. Using
the reverse transcription-polymerase chain reac-
tion, Ziesche et al.38 showed that therapy with IFN-
g-1b decreased the levels of mRNA for TGF-b1 and
connective tissue growth factor, the main growth
factor product of TGF-b stimulation, as assessed in
transbronchial biopsy specimens obtained before
and after treatment in a sample of the study group.
This study, even though small and not placebo
controlled, heralded a new concept in IPF therapy,
namely, a treatment based more on modification of
the immune response (by using a Th1 cytokine) than
on suppression of inflammation (using corticoster-
oids). It also had the considerable merit of
stimulating a larger, randomized, multicentre study
on IPF therapy, discussed next.
This phase III randomized, double-blind, placebo-
controlled, multinational trial of 330 patients with
a definite diagnosis of IPF/UIP, was based on the
findings of a lung biopsy for most patients or the
consensus diagnostic criteria.4 The study aimed at
evaluating the safety and efficacy of IFN-g-1b in IPF.
Progression-free survival, defined as the time to
disease progression or death, was the primary
efficacy end point.39 Over a median of 58 weeks,
IFN-g therapy did not significantly affect the
primary end point of survival, and no significant
effects on measures of lung function, gas exchange,
or quality of life were observed. Ten percent of
patients in the IFN-g group died, compared with
17% of patients in the placebo group (P ¼ 0:08)
(Fig. 2). Treatment with IFN-g was also associated
with more frequent constitutional symptoms and
the occurrence of pneumonia, but the incidence of
severe life-threatening respiratory tract infections
F. Luppi et al.1042was similar in the two groups.39 These findings
differed from those of the previous study;38 a
possible explanation for the discrepancy is a
potential selection bias due to the lack of expres-
sion for IFN-g in the transbronchial biopsy speci-
mens of all patients in the 1999 study.
Nevertheless, a statistical trend favouring the
IFN-g group was detected (relative risk reduction
of 41%) in the 1-year study.39 Further analysis of
this cohort of IPF patients after a follow-up period
of 3 years suggested that those patients with less
severe disease (FVC460%) potentially derive a
greater benefit from therapy with IFN-g. These
results are concordant with the finding of a more
pronounced toxicity of IFN-g in patients with
advanced IPF,40 many of whom also developed
irreversible acute respiratory failure shortly after
initiation of IFN-g therapy.41Colchicine
Among its biological effects, colchicine reduces
procollagen synthesis by impairing its cellular
secretion.42 Collagenolytic activity is also en-
hanced, with increased collagenase production.
Colchicine induces mitotic arrest and inhibits DNA
synthesis. Finally, colchicine inhibits cell-mediated
immune responses by inhibiting immunoglobulin
secretion, interleukin-1 production, histamine re-
lease, HLA-DR expression,42 and alveolar macro-
phage release of two mediators that are associated
with the development of fibrosis: fibronectin and
alveolar macrophage-derived growth factor, which
stimulate fibroblast proliferation.43 For this reason,
colchicine has been hypothesized to have a role in
IPF treatment.
Douglas et al.44 carried out a multicentre,
unblinded, randomized, prospective, parallel study
of 26 symptomatic people with clinical evidence
plus either HRCT (n ¼ 25) or open-lung biopsy
(n ¼ 1) patterns typical of IPF, to evaluate and
compare the efficacy of colchicine vs. prednisone
as single-drug therapy. Twelve patients received
high-dose prednisone, and 14 patients received
colchicine. The minimum dose of prednisone used
was 60mg/day for 1 month, tapering to 40mg/day
over the second month and 40mg on alternate days
during the third month, with subsequent doses
adjusted as clinically indicated. The dose of
colchicine was 0.6–1.2mg/day, as tolerated. Parti-
cipants treated with high-dose prednisone experi-
enced a higher incidence of serious side-effects and
exhibited a trend (though not statistically signifi-
cant) to more rapid decline of pulmonary function
and shortened survival compared with peopletreated with colchicine. In most participants with
typical clinical and HRCT features of IPF, neither
prednisone nor colchicine resulted in objective
improvement, and the disease continued to pro-
gress in most people. In conclusion, there is no
evidence to suggest that colchicine is any more
effective in the treatment of IPF than is prednisone
alone. Colchicine did seem to be better tolerated
than oral corticosteroids in the trial.
Other drugs
Cyclosporine, penicillamine and pirfenidone have
been used alone or as an adjunct in the manage-
ment of IPF. No randomized-controlled trials have
been carried out for these drugs. Therefore, at the
moment, there is no good evidence that they are of
benefit in IPF treatment. However, a number of
trials are ongoing. For other treatments, studies
with the endothelin 1 antagonist bosentan, the
antioxidant N-acetylcysteine and the anti-TNF-a
etanercept are ongoing. Trials with statins (which
induces fibroblast apoptosis) and ACE-inhibitors
(which mainly inhibits fibroblast procollagen synth-
esis) are ongoing or planned in the future.Conclusions
Although the current consensus statements recom-
mend a combination of anti-inflammatory and
immunosuppressive therapy for patients with IPF,
there is little high-quality evidence that these drugs
are better than no treatment at all. Therefore,
there is little rationale for treating IPF patients with
steroids, unless the diagnosis is uncertain or the
characteristics of the particular patient are atypical.
As some other forms of interstitial pneumonia (in
particular NSIP) may respond better to immunosup-
pressive agents and steroids, it remains crucial to
obtain an accurate diagnosis of IPF/UIP, possibly in
the early stages of the disease, before the end-stage
fibrotic disease becomes predominant and makes
any intervention less effective, if not harmful. Even
though IPF/UIP has a very poor prognosis, and there
is a lack of evidence for drug therapy, a small
number of patients with IPF may benefit from lung
transplantation. The option of lung transplantation
for IPF is, however, a result of failure to find a
therapy for this disease, and its usefulness in this
group is obviously limited by patient eligibility,
morbidity and mortality of the procedure and the
supply of donor organs.
As for which therapy to choose for our patients,
any recommendation must now be made on an
individual basis. Advancement of the basic knowl-
Corticosteroid and immunomodulatory agents in IPF 1043edge of the pathogenetic mechanisms causing IPF
should eventually result in a larger number of
effective therapeutic options. Even if the goal of
cure for IPF remains elusive,45 the good news for
patients affected by this deadly disease, and for
their physicians, resides in the forthcoming well-
designed, randomized, large controlled trials with
IFN-g and other immunomodulatory agents.Research directions
 High-quality trials are lacking for the most
commonly used agents, and the results of
interventions have been greatly disappoint-
ing.
 The most pressing need is for additional
clinical trials to better evaluate treatments
for IPF.
 These future trials ideally should use pa-
tients with biopsy-proven IPF/UIP in the
early stages of disease. These trials should
have three arms: a placebo arm, an oral
corticosteroid arm and a third arm using the
agent of interest, either as a single agent or
together with oral corticosteroids.
 Such trials would need to examine a number
of clinically relevant outcomes in rando-
mized trials over a considerable period of
time (3–5 years). The outcomes of interest
should include survival, changes in lung
function and quality-of-life indices.Practice points
 IPF is a specific form of chronic fibrosing
interstitial pneumonia limited to the lung,
associated with the histological pattern of
UIP on surgical lung biopsy.
 Although current guidelines, based upon
consensus, indicate prednisone associated
with azathioprine or cyclophosphamide as
the basis for IPF treatment, it is commonly
observed that these drugs are ineffective in
most of these patients.
 Using the methodologies of the Cochrane
collaboration, no high-quality studies on
oral corticosteroids, the most commonly
used medical therapy for IPF, have been
identified. Furthermore, only few small
studies have used non-steroid immunosup-
pressive agents, and the results have been
disappointing.
 In a recent randomized, double-blind, pla-
cebo-controlled, multinational trial IFN-gtherapy did not significantly affect the
primary end point of survival. Further
analysis of this cohort of IPF patients after
a follow-up period of 3 years suggests that
those patients with less severe disease could
have a greater benefit from therapy with
IFN-g. Therefore, further trials using IFN-g in
IPF patients might provide in the future
additional evidence regarding its usefulness.
 Because of its poor prognosis, there is a
major need for additional clinical trials to
better evaluate new therapies for IPF.Acknowledgements
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